Cruz PF, Webb WK, Vilchez LM, Espinoza AA

Language: Spanish
References: 19
Page: 1-4
PDF size: 229.20 Kb.

ABSTRACT

Eosinophilic myocarditis (EM) was first described in 1936 by Wilhelm Löeffler. This pathology presents an infiltration of eosinophils in myocardium, with hypereosinophilia association or not, with several etiologies described, and even cases of unknown cause. The clinical presentation of this pathology can be a little symptomatic, until presenting heart failure or death, can also develop restrictive cardiomyopathy by fibrosis. The definitive diagnosis is made by endomyocardial biopsy, where the histology shows infiltrates of eosinophils and necrosis of myocytes. The most used treatment in this pathology are corticosteroids with good results in most cases.

REFERENCES

1. W. Löeffler, Scientific raisins from 125 years SMW (Swiss Medical Weekly). 2nd international medical week dedicated in Switzerland. Luzern, 31 August–5 September 1936. Fibroplastic parietal endocarditis with eosinophilia. An unusual disease. 1936, Schweiz. Med. Wochenschr. 125 (1995) 1837–1840.

2. Fench A Weller C. Interstitial myocarditis following the clinical and experimental use of sulfonamide drugs. Am J Pathol 1942;18:122.

3. Fozing T Zouri N Tost A et al. Management of a patient with eosinophilic myocarditis and normal peripheral eosinophil count: case report and literature review. Circ Heart Fail 2014;7:692–4.

4. Pollack A Kontorovich AR Fuster V. Viral myocarditis– diagnosis, treatment options, and current controversies. Nat Rev Cardiol 2015; 12:670–80.

5. Kindermann I Barth C Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012;59:779–92

6. Brambatti M Matassini M Adler E Klingel K Camici P Ammirati E. Eosinophilic Myocarditis Characteristics, Treatment, and Outcomes. JACC. 2017:2363–75

7. Burke AP Saenger J Mullick F Virmani R. Hypersensitivity myocarditis. Arch Pathol Lab Med 1991;115:764–9.

8. Xie M, Cheng T, Fei H, et al. The diagnostic value of transthoracic echocardiography for eosinophilic myocarditis: A single center experience from China. Int J of Cardiol. (2015) 353–357

9. Ginsberg F Parrillo JE. Eosinophilic myocarditis. Heart Fail Clin 2005;1:419–29.

10. Cooper L Baughman K Feldman A et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease.JACC. 2007, Nov. Vol. 50, No. 19, 6:1914-31.

11. Kindermann I Kindermann M Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118:639 – 48.

12. Cooper L. Eosinophilic Myocarditis as a Cause of Acute Cardiac Syndromes. The Importance of Awareness. JACC. 2017:2376–7

13. Baandrup U. Eosinophilic myocarditis. Herz 2012;37:849–52.

14. Boussir H, Ghalem A,Ismaili N, El ouafi N. Eosinophilic myocarditis and hypereosinophilic syndrome. J Saudi Heart Assoc 2017;29:211–213

15. Kuchynka P Palecek T Masek M, et al. Current diagnostic and therapeutic aspects of eosinophilic myocarditis. Biomed Res Int 2016;2016:2829583.

16. Sohn KH Song WJ Kim BK, et al. Eosinophilic myocarditis: case series and literature review. Asia Pac Allergy 2015;5:123–7.

17. Rodríguez M Wadnipar M Calvo L. Miocarditis eosinofílica como causa de disfunción ventricular izquierda reversible. Rev Colomb Cardiol. 2017;24(1):56.e1-56.e5

18. Lin YC Oliveira GH Villa-Forte A. Churg-Strauss syndrome a nd persistent heart failure: active disease or damage? J Clin Rhe umatol. 2013; 19:390–392

19. Fozing T Zouri N Tost A, et al. Management of a Patient With Eosinophilic Myocarditis and Normal Peripheral Eosinophil Count. Circulation. 2014;7:692–69